Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Expert review of anticancer therapy - 1 Apr 2015

Sanford David S, Kantarjian Hagop, O'Brien Susan, Jabbour Elias, Cortes Jorge, Ravandi Farhad

Abstract excerpt

The introduction of tyrosine kinase inhibitors has improved outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia, yet relapse due to the development of resistance mutations remains a major obstacle. Ponatinib is a novel tyrosine kinase inhibitor designed to overcome single-resistance mutations in the ABL kinase. Three clinical trials confirmed the efficacy of ponatinib in the relapsed and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Imidazoles

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Protein Kinase Inhibitors

Share to Pyridazines

Share to Thrombosis

Source

Identifiers

PMID: 25764322
DOI: 10.1586/14737140.2015.1025256

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.PMID 25764322Read ↗

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular ManagementSemantic proximity Read ↗

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive LeukemiasSemantic proximity Read ↗

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – final 6-year results from a Belgian registrySemantic proximity Read ↗

Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?Semantic proximity Read ↗

Ponatinib in refractory Philadelphia chromosome-positive leukemias.Semantic proximity Read ↗

Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALLSemantic proximity Read ↗

Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – Final 6-year results from a Belgian registrySemantic proximity Read ↗

Where exactly does ponatinib fit in chronic myelogenous leukemia?Semantic proximity Read ↗

Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation.Semantic proximity Read ↗

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trialSemantic proximity Read ↗

Ponatinib in the therapy of chronic myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.